Tennessee Valley Asset Management Partners Takes Position in Stryker Co. (NYSE:SYK)

Tennessee Valley Asset Management Partners bought a new stake in Stryker Co. (NYSE:SYK) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 204 shares of the medical technology company’s stock, valued at approximately $61,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Farmers & Merchants Trust Co of Chambersburg PA lifted its stake in shares of Stryker by 203.3% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 61 shares during the period. HBC Financial Services PLLC acquired a new stake in shares of Stryker in the fourth quarter valued at about $37,000. Operose Advisors LLC lifted its stake in shares of Stryker by 308.6% in the third quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock valued at $39,000 after purchasing an additional 108 shares during the period. Venturi Wealth Management LLC lifted its stake in shares of Stryker by 97.1% in the fourth quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock valued at $41,000 after purchasing an additional 67 shares during the period. Finally, Armstrong Advisory Group Inc. lifted its stake in shares of Stryker by 40.0% in the fourth quarter. Armstrong Advisory Group Inc. now owns 140 shares of the medical technology company’s stock valued at $42,000 after purchasing an additional 40 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of NYSE SYK opened at $327.68 on Tuesday. The company has a market cap of $124.67 billion, a PE ratio of 39.72, a price-to-earnings-growth ratio of 2.62 and a beta of 0.89. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $361.41. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. The company has a 50-day simple moving average of $349.74 and a 200-day simple moving average of $313.59.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The company’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.00 earnings per share. On average, equities analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a $0.80 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a yield of 0.98%. Stryker’s payout ratio is 38.79%.

Insider Activity at Stryker

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the sale, the director now owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The disclosure for this sale can be found here. Over the last three months, insiders sold 212,109 shares of company stock worth $72,845,768. 5.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

SYK has been the subject of several recent analyst reports. Wells Fargo & Company raised their price objective on shares of Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research note on Wednesday, January 31st. Evercore ISI raised their price objective on shares of Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Royal Bank of Canada raised their price objective on shares of Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Finally, Citigroup lifted their target price on shares of Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $340.45.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.